SciClone Pharmaceuticals (Holdings) Limited announced that, on December 13, 2022, Ms. Li Quan has tendered her resignation as a non-executive Director and a member of the audit committee of the Board (the "Audit Committee") with effect from December 19, 2022 due to personal work arrangement. Ms. Li Quan has confirmed that she has no disagreement with the Board, nor is there any matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). The Company is in the process of identifying and appointing suitable candidate to fill the vacancy of the Audit Committee upon Ms. Li Quan's resignation becoming effective to comply with the relevant requirements pursuant to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules") and will make further announcement(s) as and when appropriate in accordance with the Listing Rules.

The Board would like to take this opportunity to expresses its gratitude to Ms. Li Quan for her contribution and service to the Company during her tenure of office.